Johnson & Johnson $JNJ Shares Sold by Equitable Holdings Inc.

Equitable Holdings Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 15.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 144,824 shares of the company's stock after selling 25,728 shares during the quarter. Equitable Holdings Inc.'s holdings in Johnson & Johnson were worth $36,781,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Centaurus Financial Inc. raised its position in Johnson & Johnson by 49.5% in the second quarter. Centaurus Financial Inc. now owns 12,384 shares of the company's stock valued at $3,145,000 after purchasing an additional 4,103 shares during the period. Graybill Wealth Management LTD. boosted its holdings in Johnson & Johnson by 1.6% during the 2nd quarter. Graybill Wealth Management LTD. now owns 29,954 shares of the company's stock valued at $7,607,000 after acquiring an additional 479 shares during the period. Fayez Sarofim & Co grew its position in Johnson & Johnson by 5.7% in the 2nd quarter. Fayez Sarofim & Co now owns 688,542 shares of the company's stock valued at $174,869,000 after acquiring an additional 37,213 shares in the last quarter. Redwood Investment Management LLC increased its stake in Johnson & Johnson by 4.6% during the second quarter. Redwood Investment Management LLC now owns 5,960 shares of the company's stock worth $1,514,000 after purchasing an additional 263 shares during the period. Finally, Parvin Asset Management LLC lifted its position in shares of Johnson & Johnson by 6.1% during the second quarter. Parvin Asset Management LLC now owns 3,470 shares of the company's stock worth $881,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on JNJ shares. Guggenheim upped their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Argus set a $300.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 29th. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $272.83.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company's stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 97,569 shares of company stock valued at $25,476,044 over the last 90 days. Insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $275.12 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The business has a 50 day simple moving average of $262.32 and a 200-day simple moving average of $245.30. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $281.07. The stock has a market capitalization of $663.01 billion, a PE ratio of 31.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period last year, the firm posted $2.77 EPS. Johnson & Johnson's quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is currently 62.11%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.